The Latest Cardiac and Vascular News
BRAINTREE, Mass., Jan. 26, 2024 /PRNewswire/ — PrepMD, the leading cardiac healthcare solutions provider, announced today the accreditation of their online healthcare training programs for Nursing Continuing Education Units (CEUs). Achieved in collaboration with Gladwell CME, a pioneer…
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical trial of aficamten in patients with hypertrophic cardiomyopathy (HCM). In many patients with […]
DUBLIN–(BUSINESS WIRE)–CroíValve, an Irish-U.S. based medical device company with a novel, transcatheter solution for tricuspid regurgitation (TR), today announced initiation of its Early Feasibility Study (EFS) for the DUO™ Tricuspid Coaptation Valve System, following FDA IDE and CMS approval. The TANDEM II trial is a prospective, multi-center, non-randomized single-arm study […]
MOUNTAIN VIEW, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) — HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) precision coronary solutions, announced FFRCT was transitioned to a Category I Current Procedural Terminology (CPT®) code beginning January 1, 2024. The new code, designated by The American Medical Association (AMA), supports FFRCT […]
MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the digital leader in preventive heart health, today released its inaugural Why Heart Health Matters Report, which examines the toll that cardiovascular disease (CVD) takes on employers, health plans, and the people they serve. The report surveyed 300 benefits leaders at large employers and health plans […]
REHOVOT, Israel–(BUSINESS WIRE)–Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today it received Breakthrough Device Designation from the US Food and Drug Administration for ShortCut™ – the world’s first dedicated leaflet modification device facilitating valve-in-valve Transcatheter Aortic Valve Replacement […]
LOS ANGELES–(BUSINESS WIRE)–Non-invasive cardiac assessment company Sensydia announced today that it has completed its 50-subject development study at the University of Minnesota (UMN). This study was conducted at UMN to collect data for its innovative AI-powered, non-invasive Cardiac Performance System (CPS™) that uses heart sound analysis to enable earlier detection and more effective therapy […]
UTRECHT, The Netherlands, January 16, 2024–(BUSINESS WIRE)–AM-Pharma B.V. today announced that the first patients have been treated in a Phase 2 clinical study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as a preventive treatment for cardiac surgery-associated renal damage (CSA-RD). With over 2 million open heart surgeries1 performed worldwide every year, CSA-RD […]
OXFORD, England, Jan. 10, 2024 /PRNewswire/ — Ultromics, a patient outcomes-focused AI-driven health technology company with roots at the University of Oxford, UK, has entered into an agreement with Pfizer to support the validation and FDA clearance of its AI-based technology for the…
DENVER–(BUSINESS WIRE)–Cleerly, the company working to create a new standard of care for the diagnosis of heart disease, today announced the launch of Cleerly ISCHEMIA, which recently received U.S. Food and Drug Administration (FDA) 510(k) medical device clearance. Cleerly ISCHEMIA analysis software is an automated machine learning-based decision support tool, intended […]
